Meeting
2021 ASCO Annual Meeting
A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.
Authors
Komal L. Jhaveri
Memorial Sloan Kettering Cancer Center, New York, NY
Komal L. Jhaveri , Elgene Lim , Erika P. Hamilton , Cristina Saura , Tarek Meniawy , Rinath Jeselsohn , J. Thaddeus Beck , Peter A. Kaufman , Sarah Sammons , Kalyan Banda , Meena Okera , Kan Yonemori , Kathleen Kiernan Harnden , Sung-Bae Kim , Joohyuk Sohn , Cynthia X. Ma , Philippe Georges Aftimos , Xuejing Aimee Wang , Suzanne R.L. Young , Muralidhar Beeram
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04188548
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1050)
DOI
10.1200/JCO.2021.39.15_suppl.1050
Abstract #
1050
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
First Author: Komal L. Jhaveri
Poster
2020 ASCO Virtual Scientific Program
A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.
First Author: Elgene Lim
Poster
2023 ASCO Annual Meeting
VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.
First Author: Mario Campone
Poster
2023 ASCO Annual Meeting
TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.
First Author: Rachel M. Layman